The COVID-19 crisis has consequences not only for those who have become infected and the doctors and nurses who care for them. The care of other patients is also threatened by the increasing stress that national health systems and societies as a whole are under.

Ruben Mesa, MD

Newly approved and investigational agents are joining ruxolitinib (Jakafi) for the treatment of myelofibrosis (MF) and may provide options for patients who progress or become intolerant to frontline JAK inhibitors.

At the 24th Annual International Congress on Hematologic Malignancies, hosted by Physicians’ Education Resource®, LLC, Ruben Mesa, MD, who is director of the UT San Antonio MD Anderson Cancer Center, presented available and emerging therapy options for patients who require additional MF therapy following ruxolitinib.

(continued)

Coronavirus 2019: What People With Cancer Need to Know

Merry Jennifer Markham, MD, FACP
March 25, 2020 · Merry Jennifer Markham, MD, FACP
This post is reviewed and updated every day. It was first published on March 3.

The outbreak of coronavirus disease 2019 (COVID-19) may be stressful for people and communities. Fear and anxiety about a disease can be overwhelming and cause strong emotions in adults and children. Information follows about how to cope with mental health and stress and anxiety during this time:

(Links follow)

Join The Mighty’s staff and community for a series of events designed to put the SOCIAL in social distancing. We’ve got writing workshops, fun events for kids, interactive Facebook Lives, and more!

Check out the schedule (con't)

Hospice is the gold standard of care for patients near the end of life. But patients with blood cancers too often are unable to reap the benefits of that comforting option because of obstacles confronting those suffering from or treating hematologic malignancies.

The U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued warning letters to seven companies for selling fraudulent COVID-19 products.  These products are unapproved drugs that pose significant risks to patient health and violate federal law.  The FDA and FTC are taking this action as part of their response in protecting Americans during the global COVID-19 outbreak. The warning letters are the first to be issued by the FDA for unapproved products intended to prevent or treat “Novel Coronavirus Disease 2019” (COVID-19).

Key Points
In patients with newly diagnosed mIDH1 AML (median age, 76 years), ivosidenib monotherapy achieved median overall survival of 12.6 months.